Total Payments
$94,420
2024 Payments
$3,200
Companies
6
Transactions
75
Payment Breakdown by Category
Consulting$69,822 (73.9%)
Research$11,280 (11.9%)
Other$6,960 (7.4%)
Travel$4,515 (4.8%)
Food & Beverage$1,812 (1.9%)
Education$32.27 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $69,822 | 16 | 73.9% |
| Unspecified | $11,280 | 6 | 11.9% |
| Honoraria | $6,630 | 1 | 7.0% |
| Travel and Lodging | $4,515 | 19 | 4.8% |
| Food and Beverage | $1,812 | 31 | 1.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $330.00 | 1 | 0.3% |
| Education | $32.27 | 1 | 0.0% |
Payments by Type
General
$83,140
69 transactions
Research
$11,280
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Global Blood Therapeutics, Inc. | $41,384 | 20 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $29,128 | 27 | $0 (2021) |
| PFIZER INC. | $10,231 | 7 | $0 (2024) |
| CSL Behring | $9,730 | 6 | $0 (2019) |
| Novo Nordisk Inc | $2,472 | 2 | $0 (2021) |
| AstraZeneca UK Limited | $1,475 | 13 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,200 | 1 | PFIZER INC. ($3,200) |
| 2023 | $940.00 | 1 | PFIZER INC. ($940.00) |
| 2022 | $26,835 | 11 | Global Blood Therapeutics, Inc. ($26,835) |
| 2021 | $19,989 | 12 | Global Blood Therapeutics, Inc. ($14,549) |
| 2020 | $6,002 | 4 | PFIZER INC. ($4,140) |
| 2019 | $18,533 | 15 | Novartis Pharmaceuticals Corporation ($15,678) |
| 2018 | $18,346 | 26 | Novartis Pharmaceuticals Corporation ($9,445) |
| 2017 | $574.49 | 5 | Novartis Pharmaceuticals Corporation ($574.49) |
All Payment Transactions
75 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | OXBRYTA (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: OXBRYTA CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 05/09/2023 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: INCLACUMAB CLINICAL PUBLICATION PROGRAM | ||||||
| 07/05/2022 | Global Blood Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,874.00 | General |
| 06/28/2022 | Global Blood Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,604.00 | General |
| 06/28/2022 | Global Blood Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,453.64 | General |
| 06/14/2022 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $3.28 | General |
| Category: Sickle Cell Disease | ||||||
| 05/27/2022 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $2.36 | General |
| Category: Sickle Cell Disease | ||||||
| 04/21/2022 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $4.78 | General |
| Category: Sickle Cell Disease | ||||||
| 04/12/2022 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Consulting Fee | Cash or cash equivalent | $4,230.00 | General |
| Category: Sickle Cell Disease | ||||||
| 04/12/2022 | Global Blood Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $475.00 | General |
| 03/30/2022 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Consulting Fee | Cash or cash equivalent | $2,585.00 | General |
| Category: Sickle Cell Disease | ||||||
| 03/30/2022 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Consulting Fee | Cash or cash equivalent | $2,585.00 | General |
| Category: Sickle Cell Disease | ||||||
| 01/24/2022 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: Sickle Cell Disease | ||||||
| 11/17/2021 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Consulting Fee | Cash or cash equivalent | $4,230.00 | General |
| Category: SICKLE CELL DISEASE | ||||||
| 11/11/2021 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $46.09 | General |
| Category: SICKLE CELL DISEASE | ||||||
| 10/14/2021 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Consulting Fee | Cash or cash equivalent | $470.00 | General |
| Category: SICKLE CELL DISEASE | ||||||
| 09/30/2021 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Consulting Fee | Cash or cash equivalent | $4,700.00 | General |
| Category: SICKLE CELL DISEASE | ||||||
| 09/30/2021 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: SICKLE CELL DISEASE | ||||||
| 09/23/2021 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $27.56 | General |
| Category: SICKLE CELL DISEASE | ||||||
| 06/30/2021 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Consulting Fee | Cash or cash equivalent | $4,935.00 | General |
| Category: SICKLE CELL DISEASE | ||||||
| 06/30/2021 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $39.32 | General |
| Category: SICKLE CELL DISEASE | ||||||
| 06/24/2021 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $35.93 | General |
| Category: SICKLE CELL DISEASE | ||||||
| 04/16/2021 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| 03/01/2021 | Novartis Pharmaceuticals Corporation | ADAKVEO (Biological) | — | In-kind items and services | $1,600.00 | Research |
| Study: A LONGITUDINAL STUDY FOR VALIDATION OF THE SICKLE CELL PAIN DIARY - SELF REPORT (SCPD-S). • Category: HEMATOLOGY | ||||||
| 01/06/2021 | PFIZER INC. | — | — | In-kind items and services | $1,400.00 | Research |
| Study: RIVIPANSEL CLINICAL PUBLICATION PROGRAM | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RIVIPANSEL CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $5,540 | 3 |
| OXBRYTA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A LONGITUDINAL STUDY FOR VALIDATION OF THE SICKLE CELL PAIN DIARY - SELF REPORT (SCPD-S). | Novartis Pharmaceuticals Corporation | $1,600 | 1 |
| INCLACUMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
About Robert Brown, MD, PHD
Robert Brown, MD, PHD is a Hematology & Oncology healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1871539825.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Robert Brown, MD, PHD has received a total of $94,420 in payments from pharmaceutical and medical device companies, with $3,200 received in 2024. These payments were reported across 75 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($69,822).
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Atlanta, GA
- Active Since 06/20/2006
- Last Updated 06/06/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1871539825
Products in Payments
- OXBRYTA (Drug) $27,178
- ADAKVEO (Biological) $18,484
- CRIZANLIZUMAB (Biological) $9,310
- BRILINTA (Drug) $1,475
- PROMACTA (Drug) $209.16
- Afstyla (Biological) $125.00
- KYMRIAH (Biological) $102.10
- ILARIS (Biological) $33.40
- NovoSeven RT (Biological) $32.27
- ENTRESTO (Drug) $5.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Atlanta
Dr. Jonathon Cohen, M.d, M.D
Hematology & Oncology — Payments: $330,523
Hematology & Oncology $330,523
Dr. Ajay Nooka, M.d., M.p.h.,F.a.c.p, M.D., M.P.H.,F.A.C.P
Hematology & Oncology — Payments: $256,358
Hematology & Oncology $256,358
Dr. Rodolfo Bordoni, Md, MD
Hematology & Oncology — Payments: $240,507
Hematology & Oncology $240,507
Dr. Mehmet Bilen, M.d, M.D
Hematology & Oncology — Payments: $134,196
Hematology & Oncology $134,196
Olatunji Alese, M.d, M.D
Hematology & Oncology — Payments: $131,083
Hematology & Oncology $131,083
Dr. Carlos Franco, Md, MD
Hematology & Oncology — Payments: $115,439
Hematology & Oncology $115,439